• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Turkey Pharmaceuticals and Healthcare Report Q2 2009 - Product Image

Turkey Pharmaceuticals and Healthcare Report Q2 2009

  • ID: 941871
  • April 2009
  • Region: Turkey
  • 85 Pages
  • Business Monitor International


  • Abdi Ýbrahim
  • AstraZeneca
  • Biomeks
  • GlaxoSmithKline
  • Novartis
  • Pharmaceuticals
  • MORE

Turkey Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Turkey's pharmaceuticals and healthcare industry.

Outside the BRIC (Brazil, Russia, India, China) states, Turkey is considered one of the key growth pharmaceutical markets globally. Growth has been rapid in recent years, with per capita spending reaching US$159 in 2008, a similar level to other emerging countries in Eastern Europe. The country’s large, ageing and increasingly urbanised population, means both demand and access to medicines should increase in the future. Over the next five years, sales of pharmaceuticals, which include prescription drugs and over-the-counter (OTC) medicines, will increase from US$11.3bn to US$19.5bn, representing a compound annual growth rate (CAGR) of 11.6%.

Despite positive market and environmental dynamics, Turkey ranks only fifth in the Pharmaceutical Business Environment Rankings for Q209. The core reasoning behind this is the still considerable risks present in operating in the country. A negative regulatory climate is a key drawback for multinationals. Delays in bringing products to market, unfavourable pricing regimes READ MORE >


  • Abdi Ýbrahim
  • AstraZeneca
  • Biomeks
  • GlaxoSmithKline
  • Novartis
  • Pharmaceuticals
  • MORE

SWOT Analysis.

Turkey Pharmaceuticals And Healthcare Industry SWOT

Turkey Political SWOT

Turkey Economic SWOT

Turkey Business Environment SWOT.

Pharmaceutical Business Environment Rating

Regional Pharma Business Environment Ratings

Limits Of Potential Returns

Risks To Realisation Of Returns

Turkey – Market Summ

Regulatory Regime.

Intellectual Property Regime

Intellectual Property Shortcomings

Counterfeit Drugs

Pricing Regime

Table: Turkish Pharmacy And Wholesale Mark-Ups.

Reimbursement Regime

Sector Developments.


Table: Disease Burden In CEE

Healthcare Sector

Healthcare Expenditure.

Healthcare Sector Reforms

Health Insurance

Private Healthcare Sector

Pharmaceutical Sector.

Pharmaceutical Retail And Distribution

Recent Pharmaceutical Sector Developments

International Co-operation

Research And Development Sector

Table: Turkey’s New R&D Law.

Medical Devices.

Recent Medical Devices Industry Developments

Industry Forecast Scenario

Overall Market Forecast

Table: Turkey – Drug Expenditure Indicators, 2004-2013

Key Growth Factors – Industry

Table: Turkey – Healthcare Expenditure Indicators, 2004-2013.

Key Growth Factors – Macroeconomic

Table: Turkey – Economic Activity

Prescription Market Forecast

Table: Turkey – Prescription Market Indicators, 2004-2013 (TRYmn unless otherwise stated)

OTC Market Forecast

Table: Turkey – OTC Market Indicators, 2004-2013 (TRYmn unless otherwise stated)

Patented Drug Market Forecast

Table: Turkey – Patented Market Indicators, 2004-2013

Generic Drug Market Forecast

Table: Turkey – Generics Market Indicators, 2004-2013

Export/Import Market Forecasts

Table: Turkey – Pharmaceutical Trade Indicators, 2004-2013 (US$mn)

Other Healthcare Data

Table: Turkey – Other Healthcare Indicators, 2004-2013.

Competitive Landscape.

Table: Top 10 Pharmaceutical Companies In Turkey By Market Share, MAT July 2008

Company Profiles.








Merck & Co

Indigenous Companies.

Abdi Ýbrahim

Eczacibaºi Pharmaceuticals

Sanovel Pharmaceuticals.

EastPharma (formerly Deva Holding)

Actavis (formerly Fako)


Country Snapshot: Turkey Demographic Data

Section 1: Population.

Table: Demographic Indicators, 2005-2030

Table: Rural/Urban Breakdown, 2005-2030

Section 2: Education And Healthcare

Table: Education, 2002-2005

Table: Vital Statistics, 2005-2030

Section 3: Labour Market And Spending Power

Table: Employment Indicators, 2001-2006

Table: Consumer Expenditure, 2000-2012 (US$)

BMI Forecast Modelling.

How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview.

Table: Pharmaceutical Business Environment Indicators


Table: Weighting Of Components


- Novartis

- Sanofi-Aventis

- GlaxoSmithKline

- Pfizer

- Roche

- AstraZeneca

- Bayer

- Merck & Co

- Abdi Ýbrahim

- Eczacibasi

- Pharmaceuticals

- Sanovel Pharmaceuticals

- EastPharma (formerly Deva Holding)

- Actavis (formerly Fako)

- Biomeks

Note: Product cover images may vary from those shown



Our Clients

Our clients' logos